Quick Answer
Tvardi Therapeutics, Inc. reported Earnings Per Share Diluted of $3.26 (loss) per share for the year ending 2025.
- Tvardi Therapeutics, Inc. showed an increase of +71.5% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Tvardi Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 8 years of available data (2018 to 2025), Tvardi Therapeutics, Inc.'s Earnings Per Share Diluted has declined by 58.3%.
- Historical annual values: Fiscal year 2025: $3.26 (loss) per share | Fiscal year 2024: $11.42 (loss) per share | Fiscal year 2023: $26.26 (loss) per share | Fiscal year 2022: $19.12 (loss) per share | Fiscal year 2021: $1.74 (loss) per share | Fiscal year 2020: $0.18 per share | Fiscal year 2019: $2.49 (loss) per share | Fiscal year 2018: $2.06 (loss) per share.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: